PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31

PROTHENA CORP PUBLIC LTD CO

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$8.48+0.13 (+1.56%)

Close on Oct 19, 2026

Market cap: $442.19M
P/E (TTM): –
Dividend yield: –

PROTHENA CORP PUBLIC LTD CO income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	9.68	135	91	54	201	0.85	0.81	0.96	28	1.06	1.61	51	0.68	2.66	–
Research & Development	135	223	221	136	82	75	51	101	135	120	58	38	26	34	24
General & Administrative	59	67	62	50	46	39	36	42	48	41	23	19	15	9.93	5.58
Operating Expenses	224	290	282	185	129	114	87	160	183	161	82	58	41	44	30
Operating Income	-215	-155	-191	-132	72	-113	-86	-159	-155	-160	-80	-6.65	-40	-41	-29
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	0.20	0.08	0.07	0.01	0
Other Non-Operating Income	14	26	31	5.95	-0.05	1.31	8.40	2.74	-2.35	0.57	0.03	0.31	-0.15	0.01	0
Merger & Restructuring Charges	30	0	0	–	0	0	-0.06	16	0	0	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.10	0	-0.02	0.00	0	0	0	-0.58	0.01	0	-0.02	0.02	0.03	0	0
Pretax Income	-201	-129	-160	-126	72	-111	-77	-156	-158	-159	-80	-6.34	-41	-41	-29
Income Tax Expense	43	-6.62	-13	-8.66	4.95	-0.28	0.38	-0.47	-4.37	1.14	0.70	0.81	0.42	0.01	0.43
Net Income	-244	-122	-147	-117	67	-111	-78	-156	-153	-160	-81	-7.15	-41	-41	-30
EPS (Basic)(per share)	-4.53	-2.27	-2.76	-2.47	1.51	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-2.05
EPS (Diluted)(per share)	-4.53	-2.27	-2.76	-2.47	1.38	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-2.05
Shares Outstanding (Basic, Weighted)(shares)	54	54	53	47	44	40	40	40	38	34	30	25	19	15	14
Shares Outstanding (Diluted, Weighted)(shares)	54	54	53	47	48	40	40	40	38	34	30	25	19	15	14
EBITDA	-214	-154	-190	-131	73	-111	-84	-156	-152	-157	-79	-5.91	-40	-41	-29
Net Interest Income	14	26	31	6.35	0.04	1.37	8.20	2.69	-0.14	0.56	0.20	0.08	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -101.8%
Net margin: -80.7%
Return on equity, FY2025: -63.6%

Financial strength

Current ratio: 25.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2472.1%

Valuation

P/E ratio: –
Price to sales: 8.11
Price to book: 1.54
Dividend yield: –